Plain-English translation of NCT06695026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether RZ-001, a new experimental drug, works safely and effectively when given together with two existing medications (valganciclovir and a combination of atezolizumab with bevacizumab) to treat hepatocellular carcinoma, a type of liver cancer. The study will gradually test three different doses of the medication to find the safest and most effective amount. Researchers will watch carefully for side effects and signs that the treatment is working.
Hepatocellular carcinoma is a serious form of liver cancer, and current treatment options are limited. This trial is exploring whether combining this new medication with two existing cancer drugs might offer patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
You would join one of three groups, each testing a different dose of the new medication combined with the two existing drugs. After the first three participants have completed 6 weeks of treatment, the research team will review safety information to decide whether to move to the next dose level. You would attend study visits for safety monitoring and to check how the treatment is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Korea